Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Clinician-Selected FSH Starting Dose and Mature Oocyte Yield in Predicted Poor Responders (OPTIMAL-DOSE)

17 novembre 2026 aggiornato da: Goksu Goc, American Hospital 2 Kosovo

Association of Clinician-Selected FSH Starting Dose With Mature Oocyte Yield in Women With Predicted Poor Ovarian Response: The OPTIMAL-DOSE Prospective Cohort Study

This is a single-centre, prospective, non-interventional (observational) cohort study examining the association between the clinician-selected starting dose of follicle-stimulating hormone (FSH) and the yield of mature metaphase II (MII) oocytes in women with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number [POSEIDON] group 3 or 4) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) with a gonadotropin-releasing hormone (GnRH) antagonist protocol. The FSH dose is chosen by the treating physician as part of routine care; the study does not allocate, randomize, or change treatment. The primary outcome is the number of MII oocytes per initiated index cycle. Because dosing is not randomized, analyses are adjusted for measured confounders and address confounding by indication.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Randomized evidence in predicted poor responders (a randomized trial in predicted poor responders and the 2024 Cochrane review of individualised gonadotropin dosing) does not show improved live birth from higher follicle-stimulating hormone (FSH) dosing, so this cohort is not designed to establish comparative efficacy; its contribution is a description of real-world dose-response patterns and local gonadotropin use and cost. Consecutive eligible women are enrolled after informed consent for data use, each contributing one index cycle. The exposure is the clinician-selected starting FSH dose, analysed as a continuous variable (per 75 international units [IU]), with categories of 150 IU or less versus more than 150 IU reported descriptively and in sensitivity analyses. The primary analysis is an adjusted negative-binomial regression of the metaphase II (MII) oocyte count on exposure, with adjusted means obtained by marginal standardization and an overlap-weighted propensity analysis as sensitivity. Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statements.

Tipo di studio

Osservativo

Iscrizione (Stimato)

160

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Pristina, Kosovo, 10000
        • American Hospital Kosova
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 42 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Consecutive women aged 18 to 42 years with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 or 4: anti-Mullerian hormone below 1.2 ng/mL and/or antral follicle count below 5) undergoing a gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care at American Hospital Kosova, each contributing one index cycle.

Descrizione

Inclusion Criteria:

  1. Woman aged 18 to 42 years.
  2. Predicted poor ovarian response, Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 (under 35 years) or group 4 (35 years or older): anti-Mullerian hormone (AMH) below 1.2 ng/mL and/or antral follicle count (AFC) below 5 (both ovaries combined).
  3. Planned gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care.
  4. First eligible (index) cycle during the study period; both ovaries present.
  5. Written informed consent for data collection and processing.

Exclusion Criteria:

  1. Predicted normal or high ovarian reserve (AMH 1.2 ng/mL or higher and AFC 5 or higher).
  2. Non-antagonist protocol (for example, long GnRH-agonist).
  3. Oocyte-donation or fertility-preservation (egg-freezing) cycle.
  4. A prior cycle of the same woman already enrolled in the study.
  5. Inability to provide informed consent.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Lower starting dose (150 international units [IU] or less)

Women whose treating physician chose a starting daily follicle-stimulating hormone (FSH) dose of 150 international units (IU) or less as part of routine clinical care (observed, not assigned by the study).

FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.

Higher starting dose (more than 150 IU)

Women whose treating physician chose a starting daily FSH dose of more than 150 IU (typically 225 IU) as part of routine clinical care (observed, not assigned by the study).

FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of mature metaphase II (MII) oocytes retrieved
Lasso di tempo: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Number of metaphase II (MII) oocytes retrieved per initiated index ovarian stimulation cycle, assessed by the embryologist at a standardized time after oocyte retrieval. Compared across the clinician-selected starting-dose exposure using adjusted analysis (associations, not causal effects). Cycles cancelled before oocyte retrieval contribute zero MII oocytes in the initiated-cycle analysis. Oocytes matured in vitro are excluded from the primary count.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Total follicle-stimulating hormone (FSH) activity administered
Lasso di tempo: From the first to the last day of ovarian stimulation (up to 21 days)

Total follicle-stimulating hormone (FSH) activity administered during the index stimulation cycle, in international units (IU), by observed starting-dose exposure. FSH activity is recorded separately from luteinizing hormone (LH) and human chorionic gonadotropin (hCG) activity.

From the first to the last day of ovarian stimulation (up to 21 days)
Gonadotropin medication cost
Lasso di tempo: From the first to the last day of ovarian stimulation (up to 21 days)

Cost of the gonadotropin medication used during the stimulation cycle, in euros (EUR), calculated using a pre-specified standardized unit-price table, by observed starting-dose exposure.

From the first to the last day of ovarian stimulation (up to 21 days)
Total number of oocytes retrieved
Lasso di tempo: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Total number of oocytes retrieved at oocyte pick-up per initiated index cycle, by observed starting-dose exposure.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
Oocyte maturity rate
Lasso di tempo: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Ratio of the number of metaphase II (MII) oocytes to the total number of oocytes retrieved in the index cycle, by observed starting-dose exposure.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
Cycle cancellation before oocyte retrieval
Lasso di tempo: From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)

Whether the initiated index cycle was cancelled before oocyte retrieval, by observed starting-dose exposure.

From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)
Duration of ovarian stimulation
Lasso di tempo: From the first to the last day of ovarian stimulation (up to 21 days)

Number of days of ovarian stimulation during the index cycle, by observed starting-dose exposure.

From the first to the last day of ovarian stimulation (up to 21 days)
Number of normally fertilised oocytes with two pronuclei (2PN)
Lasso di tempo: At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)

Number of oocytes showing two pronuclei (2PN) at the fertilisation check in the index cycle, by observed starting-dose exposure.

At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)
Number of usable embryos
Lasso di tempo: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Number of embryos from the index cycle that are transferred, cryopreserved or biopsied, meeting the minimum grade of the pre-specified laboratory standard, by observed starting-dose exposure. Each embryo is counted once.

Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
Number of blastocysts
Lasso di tempo: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Number of embryos from the index cycle reaching the blastocyst stage, by observed starting-dose exposure.

Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Live birth (exploratory)
Lasso di tempo: Up to 12 months after the start of ovarian stimulation

Delivery of at least one live-born infant, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome and it is highly susceptible to confounding by indication. Reported descriptively.

Up to 12 months after the start of ovarian stimulation
Clinical pregnancy (exploratory)
Lasso di tempo: At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)

Presence of an intrauterine gestational sac on ultrasound after the first fresh or frozen embryo transfer from the index cycle, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome. Reported descriptively.

At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 ottobre 2028

Completamento dello studio (Stimato)

1 agosto 2029

Date di iscrizione allo studio

Primo inviato

11 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

17 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • OPTIMAL-DOSE-OBS-2026-001

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .